Effect of Hypertension on Outcomes of High-Risk Patients After BCG-Treated Bladder Cancer A Single-Institution Long Follow-Up Cohort Study

摘要

Immunotherapy with Bacillus Calmette Guerin (BCG) is the most efficacious treatment for high-risk bladder cancer (BC) (Ta/T1 or carcinoma in situ) to reduce the risk of recurrence. Our aim was to evaluate whether hypertension and diabetes influence the outcome of patients with noninvasive BC treated with BCG instillations.